Measuring large numbers of biomarkers in blood with new assay technologies may identify new biomarkers and physiologic pathways for cardiovascular events in people with dysglycemia and improve the ability of clinical risk factors to identify susceptible individuals.
https://ADA.apprisor.org/index.cfm?k=uaofuc07uy
